David A Shapiro
Intercept Pharmaceuticals - Chief Medical Officer · Intercept Pharmaceuticals
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David A Shapiro as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00550862 · Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)Intercept Pharmaceuticals · terminated · Liver Cirrhosis, Biliary · study director
- Ph2NCT00501592 · Study of INT-747 in Patients With Diabetes and Presumed NAFLDIntercept Pharmaceuticals · completed · Diabetes Mellitus, Type II, Fatty Liver · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 21 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:55 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.Br J Psychiatry · 2004279 citationsRCR 9.9
- Effects of treatment duration and severity of depression on the effectiveness of cognitive-behavioral and psychodynamic-interpersonal psychotherapy.J Consult Clin Psychol · 1994222 citationsRCR 9.9
- Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.Br J Psychiatry · 2004218 citationsRCR 7.2
- Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.Hepatology · 2007147 citationsRCR 3.2
- The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.Aliment Pharmacol Ther · 2015142 citationsRCR 5.2
- Pragmatic randomized trial of antenatal intervention to prevent post-natal depression by reducing psychosocial risk factors.Psychol Med · 2000121 citationsRCR 5.0
- Early sudden gains in psychotherapy under routine clinic conditions: practice-based evidence.J Consult Clin Psychol · 2003115 citationsRCR 4.0
- Dose-effect relations in time-limited psychotherapy for depression.J Consult Clin Psychol · 1996100 citationsRCR 4.3
- Impact of Cluster C personality disorders on outcomes of contrasting brief psychotherapies for depression.J Consult Clin Psychol · 199585 citationsRCR 3.8
- Outcomes of patients completing and not completing cognitive therapy for depression.Br J Clin Psychol · 200378 citationsRCR 2.9